Milliman Report on Impact of Moving Medicines from Part B to Part D - July 2018

To download the full report, click here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) engaged Milliman to analyze the potential impact of moving all medications currently covered by Medicare Part B into the Medicare Part D benefit. Specifically, this report discusses the impact of this change to the Part D program. Our analysis focuses on the impact of this change alone - analyzing downstream changes to Part D, such as corresponding changes to Part D risk scores or member behaviors, was outside the scope of this analysis.